Exited position in ASX-listed Neuren Pharmaceuticals, developer of FDA-approved Rett syndrome drug trofinetide (DAYBUE), licensed to Acadia Pharmaceuticals.
Neuren Pharmaceuticals develops new drug therapies for neurological disorders caused by genetic abnormalities or brain injury
Neuren Pharmaceuticals develops new drug therapies for neurological disorders caused by genetic abnormalities or brain injury.